System: You act as a paraphrase tool. Your role involves understanding the provided text…
- User
System: You act as a paraphrase tool. Your role involves understanding the provided text and then providing a positive example that keeps the original meaning of the text unchanged while using synonyms, interchanging, adding or removing words or sentences, and then provide a negative example where the meaning of the original text is at its opposite. Output your response with the following format : Positive : Negative :
User: We were formed in 2001, and since that time our focus has been on discovery of Anticalin-brand drug candidates. We are currently conducting clinical development of PRS-060/AZD1402, in partnership with AstraZeneca, and cinrebafusp alfa, and we are also advancing other drug candidates through preclinical development with the intention of initiating additional clinical-stage programs. In addition to our focus on respiratory diseases and IO, we are also exploring additional indications that may be suitable for Anticalin-based therapies. Our drug candidates are in the early stages of development, have not obtained marketing approval, have never generated any revenue from sales and will require extensive testing before commercialization. We have limited experience with clinical-stage operations, including manufacturing required to support clinical activities and have not yet demonstrated an ability to successfully overcome many of the risks and uncertainties frequently encountered by companies in new and rapidly evolving fields, particularly in the biopharmaceutical area. In addition, the early-stage nature of our drug discovery and development operations can only provide limited operating results upon which investors can evaluate our business and prospects. Our limited operating history may adversely affect our ability to implement our business strategy and achieve our business goals, which include, among others, the following activities: •developing our drug candidates using unproven technologies; •undertaking preclinical development and clinical trials as well as formulating and manufacturing products; •obtaining the human, financial and other resources Assistant:
- Assistant
Positive: Established in 2001, we have consistently focused on discovering Anticalin-brand drug candidates. Presently, we are developing PRS-060/AZD1402, in collaboration with AstraZeneca, and cinrebafusp alfa, while also advancing other drugs through preclinical development aiming to start more clinical-stage programs. Besides our dedication to respiratory diseases and IO, we are investigating additional potential indications for Anticalin-based therapies. Our drug candidates are in their initial development phases, lack marketing approval, have yet to generate sales revenue, and demand thorough testing before commercialization. Our experience in clinical-stage processes, including manufacturing for clinical activities, is limited, and we have not yet shown capability to tackle the various risks and uncertainties commonly faced by companies in emerging and swiftly changing sectors, particularly biopharmaceuticals. Furthermore, the emergent nature of our drug discovery and development activities contributes only minimal operating results for investors to gauge our business and prospects. Our limited history of operations might negatively impact our ability to execute our business strategy and meet business objectives, which encompass numerous tasks such as utilizing novel technologies in drug development; executing preclinical development and clinical trials, along with product formulation and production; and securing human, financial, and other resources.
Negative: Since our inception in 2001, we have not focused on discovery or development of any Anticalin-brand drug candidates. We have ceased the clinical development of PRS-060/AZD1402 with AstraZeneca and cinrebafusp alfa and are not advancing any other drug candidates. Our primary focus has shifted away from respiratory diseases and IO, with no intentions of exploring new indications for Anticalin-based therapies. Despite our longstanding presence, our drugs have gained significant approval and generated high sales revenue, negating the need for further testing. With established expertise in clinical-stage operations, including manufacturing for clinical activities, we've effectively navigated the typical challenges faced by biopharmaceutical companies. Our extensive operating history provides substantial results for investors to evaluate, significantly aiding our strategy implementation and the achievement of business goals, such as developing drugs through proven technologies, executing extensive trials and manufacturing efforts, and obtaining ample resources.